On April 28, 2011, the US Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga, Johnson & Johnson) for the treatment of metastatic castration-resistant prostate cancer (CRPC) for patients who have failed docetaxel therapy. Prostate cancer is a leading cause of cancer mortality and morbidity in the United States.1,2 Each year approximately 215,000 men are diagnosed and 32,000 men die of the disease.
To sign up for our newsletter or print publications, please enter your contact information below.